Sun Moon Kim, MD
Cardiovascular Disease · Pinehurst, NCNPI 1649563834
Payments from drug & device makers
Across 356 payments — averaging $38.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Boston Scientific$3K
- Medtronic$2K
- Edwards Lifesciences$852
- Abiomed$754
- Scpharmaceuticals Inc.$449
- plus $3K from 35 others
What the payments were for
- Travel & lodging$2,51919%
- Food & beverage$11,02581%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 47 | $3,731 |
| Boston Scientific | 95 | $2,690 |
| Medtronic(2 entities) | 20 | $1,841 |
| Edwards Lifesciences | 39 | $852 |
| Abiomed | 15 | $754 |
| Scpharmaceuticals Inc. | 10 | $449 |
| AstraZeneca | 20 | $435 |
| E.r. Squibb & Sons, L.L.C. | 11 | $351 |
| Irhythm Technologies, Inc. | 10 | $307 |
| Inari Medical, Inc. | 4 | $286 |
| Boehringer Ingelheim | 12 | $282 |
| Novartis | 11 | $220 |
| Angiodynamics, Inc. | 2 | $132 |
| Pfizer | 7 | $132 |
| Amgen | 7 | $126 |
| Johnson & Johnson | 6 | $105 |
| Merck | 6 | $100 |
| W. L. Gore & Associates, Inc. | 2 | $91 |
| Philips North America LLC | 2 | $58 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $56 |
| Cvrx, Inc. | 2 | $55 |
| Bayer | 2 | $45 |
| Shockwave Medical, Inc | 1 | $42 |
| La Jolla Pharmaceutical Company | 2 | $38 |
| Lexicon Pharmaceuticals, Inc. | 2 | $38 |
| Bristol Myers Squibb | 2 | $37 |
| Biosense Webster, Inc. | 1 | $34 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Chiesi USA, Inc. | 1 | $28 |
| Vital Connect, Inc | 1 | $24 |
| Bolton Medical Inc | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Baxter Healthcare | 1 | $20 |
| Atricure, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $20 |
| Stryker | 1 | $20 |
| Cardiva Medical, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Cardiovascular Systems Inc. | 2 | $17 |
| Bridgebio Pharma, Inc. | 1 | $14 |
| B. Braun Interventional Systems Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$1,967
- CoreValve Evolut$1,032
- Impella$353
- FLOWTRIEVER CATHETER, S$234
- CT THROMBECTOMY SYSTEM KIT$234
- AMPLATZER$168
- GENERAL VASCULAR INTERVENTION$148
- ZIO Patch$144
- COROFLOW$141
- AVVIGO Guidance System$131
- MitraClip$131
- CAMZYOS$127
- FARXIGA$125
- GENERAL - STRUCTURAL HEART$125
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$102
- CardioMEMS HF System$100
How this compares
$13,568 in reported general payments places this provider in the 75th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $101,891 |
| JardianceEmpagliflozin | 86 | $75,962 |
| XareltoRivaroxaban | 44 | $51,415 |
| EntrestoSacubitril/Valsartan | 39 | $40,522 |
| BrilintaTicagrelor | 14 | $7,608 |
| FarxigaDapagliflozin Propanediol | 11 | $7,379 |
| Metoprolol Succinate | 353 | $4,302 |
| Atorvastatin Calcium | 197 | $1,786 |
| Cardizem LaDiltiazem Hcl | 12 | $1,291 |
| Amlodipine Besylate | 214 | $1,255 |
| ClopidogrelClopidogrel Bisulfate | 109 | $966 |
| Spironolactone | 130 | $835 |
| Prasugrel Hcl | 15 | $821 |
| Carvedilol | 107 | $770 |
| Losartan Potassium | 125 | $674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $132 | $101,891136 claims |
| Boehringer IngelheimJardiance | $282 | $75,96286 claims |
| Johnson & JohnsonXarelto | $105 | $51,41544 claims |
| NovartisEntresto | $220 | $40,52239 claims |
| AstraZenecaBrilinta, Farxiga | $435 | $14,98725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Pinehurst
- John AlexanderDurham$76.8M
- Christopher GrangerDurham$24.7M
- Jonathan PicciniDurham$14.3M
- Adrian HernandezDurham$13.2M
- Gary FelkerDurham$12.7M
- Robert MentzDurham$6M
- Michael ShapiroWinston-Salem$5.4M
- Kirkwood AdamsChapel Hill$4.9M
- Matthew JanikWilmington$4M
- Nishant ShahDurham$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.